Back to top
more

Aptinyx Inc. (APTX)

(Delayed Data from NSDQ)

$3.78 USD

3.78
313,385

+0.03 (0.80%)

Updated May 3, 2019 04:00 PM ET

After-Market: $3.79 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bicycle (BCYC) up on Collaboration With Novartis for Conjugates

by Zacks Equity Research

Bicycle (BCYC) and Novartis enter into a collaboration agreement to develop, manufacture and commercialize conjugate drugs for several oncology indications. Stock soars following the news.

Vertex (VRTX) Inks Licensing Deal With CRISPR for Diabetes Drug

by Zacks Equity Research

Vertex Therapeutics (VRTX) enters into a licensing agreement with CRISPR for the latter's gene-editing technology to accelerate the development of its type I diabetes hypoimmune therapy programs.

Pharming (PHAR) Rare Disease Drug Joenja Gets FDA Nod, Stock Up

by Zacks Equity Research

Pharming Group (PHAR) obtains FDA approval for leniolisib for the treatment of a rare pediatric disease. The stock of the company is up about 33% following the same.

COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar

by Zacks Equity Research

COYA and Dr. Reddy's enter into a license agreement where the latter will source proposed biosimilar of abatacept biosimilar to Coya to develop and commercialize COYA 302.

Nurix's (NRIX) Stock Up Due to License Option Exercise by Gilead

by Zacks Equity Research

Nurix Therapeutics (NRIX) to earn an option fee of $20 million as partner Gilead exercised its option to exclusively license Nurix's investigational targeted protein degrader molecule NX 0479.

Deciphera (DCPH) Gets Breakthrough Tag for Qinlock Expanded Use

by Zacks Equity Research

The FDA grants breakthrough tag to Qinlock for treating second-line GIST patients with mutations in KIT Exon 11 and 17/18. Stock up on Tuesday in response.

Mirum's (MIRM) Livmarli Gets FDA Nod for Expanded Use, Stock Up

by Zacks Equity Research

Mirum Pharmaceuticals (MIRM) announces FDA approval of Livmarli for infants 3 months and older. Stock up 6% in response to the news.

Seagen (SGEN) Set to be Acquired by Pfizer for $43 B, Stock Up

by Zacks Equity Research

Seagen is set to be acquired by the large-cap pharma company, Pfizer, at a valuation of $43 billion. The stock is up about 15% in response to the news.

Acadia (ACAD) Gets FDA Approval for Daybue for Rett Syndrome

by Zacks Equity Research

Acadia Therapeutics (ACAD) announces the FDA approval of its Rett Syndrome drug, trofinetide, for the treatment of adult and pediatric patients two years of age and older. Going to be marketed as Daybue in the United States.

Biotech Stock Roundup: GILD's Drug News, NVAX & MRNA COVID-19 Vaccine Updates

by Zacks Equity Research

Regulatory and pipeline updates from Gilead (GILD) and Moderna (MRNA) are a few key highlights from the biotech sector during the past week.

Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal

by Zacks Equity Research

Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline

All You Need to Know About Aptinyx Inc. (APTX) Rating Upgrade to Buy

by Zacks Equity Research

Aptinyx Inc. (APTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Teladoc (TDOC) Plunges 40.3% Since Q1 Earnings Beat: Here's Why

by Zacks Equity Research

Teladoc Health's (TDOC) bet on mental health service BetterHelp is likely to generate lower yield this year.

Aptinyx (APTX) Tanks as Neuropathic Pain Study Misses Goal

by Zacks Equity Research

Aptinyx's (APTX) phase IIb study evaluating the effects of NYX-2925 in patients with painful diabetic peripheral neuropathy misses the primary endpoint. Stock falls sharply.

    Do Options Traders Know Something About Aptinyx (APTX) Stock We Don't?

    by Zacks Equity Research

    Investors need to pay close attention to Aptinyx (APTX) stock based on the movements in the options market lately.

    Has Aptinyx Inc. (APTX) Outpaced Other Medical Stocks This Year?

    by Zacks Equity Research

    Here is how Aptinyx Inc. (APTX) and Doximity (DOCS) have performed compared to their sector so far this year.

    Is Aptinyx Inc. (APTX) Outperforming Other Medical Stocks This Year?

    by Zacks Equity Research

    Here is how Aptinyx Inc. (APTX) and ICU Medical (ICUI) have performed compared to their sector so far this year.

    Is Aptinyx Inc. (APTX) Outperforming Other Medical Stocks This Year?

    by Zacks Equity Research

    Here is how Aptinyx Inc. (APTX) and Molina (MOH) have performed compared to their sector so far this year.

    Is Acer Therapeutics, Inc. (ACER) Outperforming Other Medical Stocks This Year? (Revised)

    by Zacks Equity Research

    Here is how Acer Therapeutics, Inc. (ACER) and Aptinyx Inc. (APTX) have performed compared to their sector so far this year.

    Is Aptinyx Inc. (APTX) Outperforming Other Medical Stocks This Year?

    by Zacks Equity Research

    Here is how Aptinyx Inc. (APTX) and Sensus Healthcare, Inc. (SRTS) have performed compared to their sector so far this year.

    Is Opexa Therapeutics, Inc. (ACER) Outperforming Other Medical Stocks This Year?

    by Zacks Equity Research

    Here is how Opexa Therapeutics, Inc. (ACER) and Aptinyx Inc. (APTX) have performed compared to their sector so far this year.

    Are Options Traders Betting on a Big Move in Aptinyx (APTX) Stock?

    by Zacks Equity Research

    Investors need to pay close attention to Aptinyx (APTX) stock based on the movements in the options market lately.

    Aptinyx Inc. (APTX) Reports Q4 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 16.67% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

    Aptinyx Inc. (APTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    by Zacks Equity Research

    Aptinyx Inc. (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Aptinyx (APTX) Surges on Promising Stress Disorder Study Data

    by Zacks Equity Research

    Aptinyx (APTX) is developing a NMDA receptor-targeted candidate, NYX-783, as potential treatment for post-traumatic stress disorder.